Clinical Issues in Severe AsthmaDebates and Discussions About Personalizing Patient Management
American Thoracic Society International Conference Asthma Posters and Oral Sessions. May 18-23, 2018. San Diego, California.
Bousquet J, et al. Eur Respir J. 2017;50(6):1701782.
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Bleecker ER, et al. Lancet. 2016;388(10056):2115-2127.
Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma.
Busse WW, et al. Adv Ther. May 2018 [Epub Ahead of Print].
A randomized, controlled phase 3 study, LIBERTY ASTHMA QUEST, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma.
Castro M, et al. American Thoracic Society International Conference. May 18-23, 2018. San Diego, California. Presentation Session A101. Presentation A7700.
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, et al. Lancet Respir Med. 2015;3(5):355-366.
Castro M, et al. N Engl J Med. 2018;378(26):2486-2496.
Corren J, et al. N Engl J Med. 2017;377(10):936-946.
A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
D’Amato G, et al. Ther Clin Risk Manag. 2007;3(4):613-619.
Denlinger LC, et al. Am J Respir Crit Care Med. 2017;195(3):302-313.
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S, et al. Lancet Respir Med. 2016;4(9):699-707.
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM, et al. Lancet. 2016;388(10056):2128-2141.
Israel E, Reddel HK. N Engl J Med. 2017;377(10):965-976.
Kim MA, et al. Curr Opin Allergy Clin Immunol. 2014;14(1):49-54.
Ortega HG, et al. N Engl J Med. 2014;371(13):1198-1207.
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG, et al. Lancet Respir Med. 2016;4(7):549-556
Passalacqua G, et al. Asthma Res Pract. 2015;1:6.
Porsbjerg C, Menzies-Gow, A. Respirology. 2017;22(4):651-661.
Rabe KF, et al. N Engl J Med. 2018;378(26):2475-2485.
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, et al. Lancet. 2016;388(10039):31-44
Debates and Discussions About Personalizing Patient Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Improving Outcomes for Patients with COPD
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A New Era in Precision Medicine
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement